Parasitological and Molecular Evaluation of Artemether Plus Lumefantrine (Act) For The Treatment Of Falciparum Malaria (New Halfa, Eastern Sudan

Abstract

The present study aims to provide more information on the therapeutic potential of (AL) for the treatment of uncomplicated malaria in New Halfa Eastern Sudan. Eighty three uncomplicated falicparum malaria symptomatic patients (male, female, children, and adults) were treated with AL on days 0, 1, 2, and followed for 28 days. Results showed that 95.1% were aparasitemic and afebrile from day 7 until day 28. No significant adverse effects were recorded. Late clinical failure was experienced by 4 patients (4.9%). Genotyping of Plasmodia parasite from these 4 late clinical failure (LCF) patients showed the following: 1 (25%) recrudescence, 2 (50%) new infections, and 1 patient (25%) with both recrudescence plus new infection. Therefore the true cure rate of (AL) as adjusted by PCR was 97.6%, hence AL appears to be effective and safe for the treatment of uncomplicated falicparum malaria in children and adults of both sexes in New Halfa Eastern Sudan. English Abstract